Literature DB >> 10750026

Androgen ablation results in differential regulation of transforming growth factor-beta isoforms in rat male accessory sex organs and epididymis.

K V Desai1, P Kondaiah.   

Abstract

The male accessory sex organs and epididymis regress following androgen depletion, although the onset of apoptosis varies temporally depending upon the tissue type. Transforming growth factor-beta1 (TGF-beta1) is an androgen-repressed gene and believed to be an apoptotic agent in the regressing rat ventral prostate (VP). Hence, in order to investigate the status of TGF-beta isoforms following castration in androgen-dependent tissues other than VP, this study was undertaken. Northern blot analysis using total RNA from these tissues of intact animals showed higher levels of TGF-beta1 expression as compared with VP, indicating a function other than that of an apoptotic agent for this isoform. Following orchiectomy, TGF-beta1 was induced in all organs studied and the levels were highest at day 3 following castration in seminal vesicle (SV) and the epididymis and decreased by day 5 despite the absence of androgens. This observation implies that TGF-beta1 might not be a truly androgen-repressed gene in these tissues. TGF-beta2 was up-regulated in VP, SV, caput and corpus epididymis but was undetectable in the dorsolateral prostate and cauda epididymis. On the other hand, TGF-beta3 expression was refractory to the androgen status in corpus epididymis and SV but was up-regulated in the remaining tissues. The castration-induced induction of mRNAs was attenuated after exogenous androgen administration. Most importantly, all the isoforms differed significantly in the time and magnitude of induction following castration, suggesting that a single hormone, testosterone, modulates the expression of TGF-betas in an isoform- and tissue-specific manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10750026     DOI: 10.1677/jme.0.0240253

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  7 in total

1.  Effect of combined hormonal and insulin therapy on the steroid hormone receptors and growth factors signalling in diabetic mice prostate.

Authors:  Wagner J Fávaro; Valéria H A Cagnon
Journal:  Int J Exp Pathol       Date:  2010-10-05       Impact factor: 1.925

2.  DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Bingcheng Wang; Thomas J Kelley; David Danielpour
Journal:  Mol Endocrinol       Date:  2010-08-25

3.  Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes.

Authors:  Makoto Yono; Mehdi Pouresmail; Wataru Takahashi; Joan F Flanagan; Robert M Weiss; Jamshid Latifpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-19       Impact factor: 3.000

4.  Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate.

Authors:  Anil M Limaye; Irfan Asangani; Thyagarajan Kalyani; Paturu Kondaiah
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

Review 5.  Seminiferous cord formation and germ-cell programming: epigenetic transgenerational actions of endocrine disruptors.

Authors:  Michael K Skinner; Matthew D Anway
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

6.  Establishment of an invasive prostate cancer model in transgenic rats by intermittent testosterone administration.

Authors:  Shinya Sato; Shugo Suzuki; Aya Naiki-Ito; Masami Komiya; Long Ne; Hiroyuki Kato; Hiroyuki Sagawa; Yoriko Yamashita; Tomoyuki Shirai; Satoru Takahashi
Journal:  J Toxicol Pathol       Date:  2014-04-30       Impact factor: 1.628

7.  The immunobiology of the mammalian epididymis: the black box is now open!

Authors:  Rachel Guiton; Joelle Henry-Berger; Joël R Drevet
Journal:  Basic Clin Androl       Date:  2013-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.